Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

This study has been completed.
Sponsor:
Information provided by:
NIH AIDS Clinical Trials Information Service
ClinicalTrials.gov Identifier:
NCT00002052
First received: November 2, 1999
Last updated: June 23, 2005
Last verified: August 1989

November 2, 1999
June 23, 2005
Not Provided
Not Provided
Not Provided
Not Provided
Complete list of historical versions of study NCT00002052 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients
Prospective Comparison of Ampicillin / Amoxicillin Versus Ceftriaxone for the Treatment of Salmonella Infections in AIDS Patients

To compare the effectiveness of standard treatment with parenteral ampicillin and oral amoxicillin compared to initial daily therapy with ceftriaxone followed by 3 times weekly suppressive treatment for salmonella infections in AIDS patients.

Not Provided
Interventional
Not Provided
Primary Purpose: Treatment
  • HIV Infections
  • Salmonella Infections
  • Drug: Ceftriaxone sodium
  • Drug: Ampicillin sodium
  • Drug: Amoxicillin trihydrate
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
Not Provided
Not Provided

Exclusion Criteria

Co-existing Condition:

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Patients with the following are excluded:

  • Type I hypersensitivity to beta-lactam antibiotics.
  • Not expected to survive 12 weeks.
  • In a coma or with other central nervous system (CNS) impairment.

Prior Medication:

Excluded within 48 hours of study entry:

  • Treatment with an antibiotic active in vitro against Salmonella.

HIV infection, AIDS, or AIDS related complex (ARC).

  • Salmonella bacteremia or positive stool culture in patient with 3 or more stools per day.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00002052
019A
Not Provided
Not Provided
University of Southern California
Not Provided
Not Provided
NIH AIDS Clinical Trials Information Service
August 1989

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP